News

Teaming Up Against Ovarian Cancer

Teaming Up Against Ovarian Cancer

September 10, 2015

Check out this guest post by Alan D. D’Andrea, MD, and Elizabeth M. Swisher, MD from the  SU2C-OCRF-OCNA-NOCC Dream Team that originally appeared on Cancer Research Catalyst, the official blog of the American Association for Cancer Research, the Scientific Partner of Stand Up 2 Cancer. September is Ovarian Cancer Awareness Month, when we scientists and advocates renew our determination to find new solutions to this devastating disease. This year we are pleased to have seen some encouraging signs. At the Annual Meeting of the American Association for Cancer Research (AACR) in April, scientists reported that a combination of two drugs, olaparib and BKM120, showed clinical benefit for women with high-grade serous ovarian cancer (as well as women with triple-negative breast cancer). Click plus sign to read on.

Community

Rachel Zoe and Husband Rodger Berman to Host OCRF's Fi...

Rachel Zoe and Husband Rodger Berman to Host OCRF's First-Ever Super Saturday Event in Las Vegas

September 1, 2015

Ovarian Cancer Research Fund’s Luxury Shopping Event to be held at Grand Canal Shoppes at The Venetian & The Palazzo and Fashion Show, September 19-20 Las Vegas, NV – Ovarian Cancer Research Fund (OCRF) will bring its popular Super Saturday shopping event to Grand Canal Shoppes at The Venetian & The Palazzo, and Fashion Show … Continued

Events

Presidential Proclamation

Presidential Proclamation

September 1, 2015

"Ovarian cancer is difficult to detect early -- there is no simple and reliable way to screen for it and symptoms are often not clear until later stages. By recognizing possible warning signs and unexplained changes, women can increase their likelihood of detecting ovarian cancer in its early stages when treatment is most effective and the chances for recovery are greatest. To bolster these efforts, my Administration has continued to invest in innovative research to improve early detection and treatment of ovarian cancer, and we are working hard to increase public awareness among women about all types of gynecological cancers." -President Barack Obama To read more, click the plus sign.

Advocacy

OCRF Research Shows Heart Medication Prolongs Life in Ovari...

OCRF Research Shows Heart Medication Prolongs Life in Ovarian Cancer Patients

August 26, 2015

(August 26, 2015) Women with epithelial ovarian cancer who happened to be taking nonselective beta-blockers for hypertension survived longer than those who were not taking the drugs, according to a large multicenter retrospective study.  The study was funded in part by an OCRF grant to Dr. Anil Sood at MD Anderson Cancer Center. Survival was … Continued

OCRA News

Multi-gene Testing for Ovarian Cancer Risk is Clinically Us...

Multi-gene Testing for Ovarian Cancer Risk is Clinically Useful

August 21, 2015

(August 21, 2015) A study published online in JAMA Oncology this month shows that screening women with a suspected risk of hereditary breast or ovarian cancer with a multigene panel (which looks for mutations in many genes), identifies more people with cancer risk related gene mutations than screening for BRCA1 and 2 alone. Importantly, identifying … Continued

Research

RAD51 Mutations Confer Moderate Risk of Ovarian Cancer

RAD51 Mutations Confer Moderate Risk of Ovarian Cancer

August 19, 2015

(August 19, 2015)  Deleterious mutations in RAD51C and RAD51D genes are associated with increased risk of epithelial ovarian cancer (EOC), according to a study published online Aug. 10 in the Journal of Clinical Oncology. Honglin Song, PhD, from the University of Cambridge in the United Kingdom, and colleagues conducted a genetic study using germline DNA … Continued

Research

OCRF Research Finds Combination Immunotherapy Promising

OCRF Research Finds Combination Immunotherapy Promising

August 19, 2015

(August 19, 2015) Whereas chemotherapy kills cancer cells only while it is being administered, immunotherapy can lead to an adaptive immune response that persists long after treatment is ceased. By simple analogy, whereas aspirin provides temporary pain relief, a polio vaccine provides lifelong protection. Unfortunately, just as tumors develop resistance to conventional therapies, tumors also … Continued

OCRA News

Ovarian Cancer Survival Rates Higher Than Thought

Ovarian Cancer Survival Rates Higher Than Thought

August 17, 2015

(August 17, 2015) A study from the University of California, Davis found that one-third of women with ovarian cancer survive at least 10 years after diagnosis. The study, published in the Journal of Obstetrics and Gynecology, linked high survival rates with younger ages, early stages, and tumor type but they also found many exceptions to … Continued

Research

New York Times Letter to the Editor

New York Times Letter to the Editor

August 13, 2015

On August 3, 2015 the New York Times published an article about the use of IP chemotherapy in the treatment of ovarian cancer. Our CEO, Calaneet Balas joined with Ovarian Cancer Research Fund CEO, Audra Moran, to write a response to the New York Times. Click the plus sign to see their Letter to the Editor.

OCRA News

The New York Times Publishes OCRF’s Letter to the Editor 8/...

The New York Times Publishes OCRF’s Letter to the Editor 8/12/15

August 12, 2015

(8/12/15) In response to the article “An Ovarian Cancer Treatment, Recommended Since 2006, is Found to be Underused,“ published in the Health section of The New York Times on August 3, 2015, OCRF co-wrote a Letter to the Editor along with Ovarian Cancer National Alliance, strongly encouraging physicians and treatment centers to fully consider and communicate all treatment … Continued

OCRA News

Ovarian Cancer Research Fund and National Sponsor QVC Expan...

Ovarian Cancer Research Fund and National Sponsor QVC Expand Woman to Woman Program

August 10, 2015

Gynecologic Cancer Patients to Receive Support in 6 New Locations WEST CHESTER, Pa (August 10, 2015) —Ovarian Cancer Research Fund (OCRF) and QVC today announced six new Woman to Woman grant recipients: Cooper University Hospital, Camden, New Jersey; Shanti Project/Kaiser Permanente, San Francisco, California; Northside Hospital Cancer Center, Atlanta, Georgia; The University of Alabama at … Continued

OCRA News

Study Finds Intraperitoneal Chemotherapy Underutilized

Study Finds Intraperitoneal Chemotherapy Underutilized

August 4, 2015

(August 4, 2015) A study published online in the Journal of Clinical Oncology reports that although the use of intraperitoneal chemotherapy (IP)/IV chemotherapy increased significantly at major cancer centers between 2003 and 2012, fewer than 50% of eligible patients received it. Previous studies have shown that the use of IP chemotherapy significantly improves survival among … Continued

Research